| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 10.4 | 7.5 |
| Net income | -23.4 | -25.1 |
| EPS (diluted, $ a share) | $-0.15 | $-0.28 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +37.4% |
|---|---|
| Operating margin | -234.3% |
10-Q filed with the SEC, NASDAQ: EDIT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Editas Medicine, Inc.: key numbers
- Share price
- $1.87Close, Nov 16
- Market cap
- $289M
- Shares outstanding
- 154.34MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Editas Medicine, Inc.
All →Editas Medicine CEO Gilmore Neil O'Neill Sells $51.1K of Stock
Gilmore Neil O'Neill, CEO, sold 21,164 shares of Editas Medicine, Inc. at $2.42 a share, worth $51.1K in total on Nov 11, 2026. Shares held after the trade: 265,592 (-7.4%).
- Value
- $51.1K
- Shares
- 21,164
- Price
- $2.42
- Role
- CEO
- Holding change
- -7.4%
- Trade date
- Nov 11, 2026
Editas Medicine EVP, CSO Linda Burkly Sells $18.9K of Stock
Linda Burkly, EVP, CSO, sold 7,814 shares of Editas Medicine, Inc. at $2.42 a share, worth $18.9K in total on Nov 11, 2026. Shares held after the trade: 70,379 (-10.0%).
- Value
- $18.9K
- Shares
- 7,814
- Price
- $2.42
- Role
- EVP, CSO
- Holding change
- -10.0%
- Trade date
- Nov 11, 2026
Editas Medicine Financial Results
Editas Medicine reported Q3 2026 financial results, highlighting a cash runway extending into the second half of 2028. The company received regulatory approval to initiate its Phase 1/2 Strive study for EDIT-401 in Australia and triggered a milestone payment from Bristol Myers Squibb following the acceptance of a second IND/CTA for their CAR T collaboration.
- Term
- Q3 2026
“We are incredibly excited by the progress we made in the third quarter as we advanced EDIT-401, our potentially best-in-class in vivo gene editing medicine for hyperlipidemia, towards the clinic.”
Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer
Editas Medicine Business Update
Editas Medicine received approval to initiate its Phase 1/2 Strive clinical trial for EDIT-401 in Australia, targeting patients with heterozygous familial hypercholesterolemia. The company expects to begin patient dosing in 2026 and report initial safety and tolerability data in the first quarter of 2027. Additionally, the company will present new preclinical data demonstrating durable LDL-C reduction at the AHA Scientific Sessions in November 2026.
- Counterparty
- Therapeutic Goods Administration